Zevra Therapeutics (ZVRA) Return on Sales (2019 - 2026)

Zevra Therapeutics has reported Return on Sales for 8 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 3.0% YoY), and the FY2025 full-year result was 0.01%, up 5.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.01%, up from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.03% in Q2 2025, with the low at 4.58% in Q2 2022.
• Historically, Return on Sales has averaged 0.29% across 5 years, with a median of 0.02% in 2022.
• Annual changes were most pronounced in 2022 — Return on Sales slumped 458 bps — and 2023, when it surged 457 bps.
• Zevra Therapeutics' Return on Sales stood at 0.16% in 2022, then soared by 90 bps to 0.02% in 2023, then tumbled by 93 bps to 0.03% in 2024, then surged by 112 bps to 0.0% in 2025, then jumped by 194 bps to 0.01% in 2026.
• The last three Return on Sales figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.